Pharvaris BV (PHVS) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Pharvaris BV stock $21.24, price $32.44, that is 34.5% below the price, quality 28 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Pharvaris BV
PHVS · USExpensive (fair value 35% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range $1.98 – $38.86 · fair‑value band $15.93 – $26.56 · the $32.44 price screens above the $21.24 fair value. As of Nov 14, 2026.
Every Wednesday you see whether Pharvaris BV is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Show moreShow less
The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Stock analysis
Pharvaris BV (PHVS) currently trades at $32.44, while our estimate is $21.24, 35% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $15.93 (bear) to $26.56 (bull), the price of $32.44 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Pharvaris BV reported revenue of €0 in FY2025 versus €0 in FY2021. Reported net income was −€176M in FY2025.
Key figures
Market cap $2.2B Mid · EPS (TTM) $−3.13 · Return on equity −70.5% · Return on assets (EBIT) −41.6% (5-year average) · Free cash flow −$137M · Net cash $291M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 37% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −35%, PHVS screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 11 officers or directors sold shares worth $27.1M and none bought.
- SaleViviane MongesDirector2× since May 21, 2026: 21,636 shares, avg. $31.82$688,389Sep 23, 2026
- SaleJohannes Gerardus Christiaan Petrus SchikanDirector6× since Apr 22, 2026: 280,800 shares, avg. $34.38$9.7MSep 22, 2026
- SaleDavid W. NassifCFO / CLO2× since May 21, 2026: 16,000 shares, avg. $32.62$521,920Sep 21, 2026
- SaleAnne LesageChief Early Development6× since Apr 22, 2026: 193,772 shares, avg. $34.44$6.7MSep 17, 2026
- SaleRobert GlassmanDirector4× since May 15, 2026: 41,160 shares, avg. $36.18$1.5MSep 17, 2026
- SaleElisabeth BjorkDirector2× since May 20, 2026: 62,500 shares, avg. $36.52$2.3MSep 17, 2026
- SalePeng LuPresident8× since Apr 22, 2026: 200,000 shares, avg. $34.74$6.9MSep 17, 2026
- SaleStefan Andreas AbeleChief Technical Ops Officer2× since May 15, 2026: 55,148 shares, avg. $36.85$2.0MSep 15, 2026
- SaleWim SouverijnsChief Commercial Officer2× since May 15, 2026: 36,090 shares, avg. $36.65$1.3MSep 15, 202610b5-1 plan
- SaleBerndt ModigChief Executive Officer, Director7× since Apr 9, 2026: 37,083 shares, avg. $29.70$1.1MSep 14, 202610b5-1 plan
Plus 1 more entries from the last 12 months.
Plus 27 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Pharvaris BV with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/B ratio by industry
- Net margin by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs PHVS |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs PHVS |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs PHVS |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs PHVS |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs PHVS |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs PHVS |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs PHVS |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs PHVS |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs PHVS |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs PHVS |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Pharvaris BV (PHVS) overvalued or undervalued?
What is the fair value of PHVS?
What is the quality score of PHVS?
What is the price target for Pharvaris BV (PHVS)?
What is the Pharvaris BV stock forecast for 2026?
What is the intrinsic value of Pharvaris BV (PHVS)?
Is Pharvaris BV stock overvalued or undervalued in 2026?
Is fair value the same as the market price of PHVS?
How much is Pharvaris BV worth?
What do the bullish and bearish scenarios say about PHVS?
How solid is the balance sheet of Pharvaris BV (PHVS)?
How far is PHVS from its 52-week high?
Which stocks are comparable to Pharvaris BV?
Is Pharvaris BV stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Pharvaris BV (PHVS)?
What should I pay attention to with Pharvaris BV right now?
Key figures of Pharvaris BV
How large is the market capitalisation of Pharvaris BV (PHVS)?
What are the earnings per share of Pharvaris BV (PHVS)?
What is the return on equity of Pharvaris BV (PHVS)?
What is the EBIT return on assets of Pharvaris BV (PHVS)?
How much free cash flow does Pharvaris BV (PHVS) generate?
How much net cash does Pharvaris BV (PHVS) hold?
Watch Pharvaris BV in the live analysis
One click puts Pharvaris BV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.